No Data
Announcement Highlights | SINGAMAS CONT's profit in 2024 increased by more than 50% year-on-year; AIA repurchased over 0.3 billion HKD in a single day.
REGENT PACIFIC issued a profit warning, expecting an annual loss attributable to Shareholders of approximately 4 million to about 5 million USD, a significant decrease in losses year-on-year; COSCO Shipping Holdings spent 54.4382 million HKD to buy back 4.8 million shares, with the buyback price ranging from 11.24 to 11.44 HKD per share.
Regent Pacific to Shrink Loss in 2024
[Company Profit Warning] REGENT PACIFIC (00575) anticipates a full-year loss of up to approximately 39 million Hong Kong dollars for 2024.
King Wu Financial News | REGENT PACIFIC (00575) announced that the Group expects to record a loss attributable to equity holders of the company of approximately 4 million USD (or about 31.2 million HKD) to approximately 5 million USD (or about 39 million HKD) for the year ending December 31, 2024, compared to a loss attributable to equity holders of the company of approximately 25.05 million USD (or about 0.195 billion HKD) for the year ending December 31, 2023, reflecting a significant reduction in losses. The changes in the unaudited consolidated final results during the reporting period compared to the corresponding period primarily stem from: (i) during the reporting period,
REGENT PACIFIC: Estimated Results for the Year Ended 31 December 2024
Regent Pacific to Change Hong Kong Share Registrar
What does AI pharmaceuticals still lack before a market explosion? | Focus
① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.
